Trials / Completed
CompletedNCT03459222
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Relatlimab | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | BMS-986205 | Specified dose on specified days |
| BIOLOGICAL | Ipilimumab | Specified dose on specified days |
Timeline
- Start date
- 2018-05-30
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
- First posted
- 2018-03-08
- Last updated
- 2026-04-06
- Results posted
- 2026-04-06
Locations
22 sites across 7 countries: United States, Australia, France, Italy, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03459222. Inclusion in this directory is not an endorsement.